Not yet recruitingInterventionalPhase 4Last updated Aug 12, 2026

Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years

Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Randomized Controlled Trial At 6 Years

Overview

ClinicalTrials.gov ID: NCT07757373
Lead Sponsor: Tuen Mun HospitalOTHER_GOV
Brief Summary: This is an extended observation study of a RCT comparing the efficacy of romorozumab and denosumab in high-risk patients using long-term glucocorticoids. In the romosozumab arm, patients were shifted to denosumab after the first year. The denosumab arm of patients were continued on denosumab. This study aims to look at the bone mineral density changes in both groups of patients after 6 years.
Study Type

Status

Study Record Dates

NCT06472050Completed

Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months

NCT04091243Completed

Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users

NCT07283887Recruiting

Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

NCT01465568Completed

Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis

NCT06938152Recruiting

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

NCT03005678Completed

Denosumab Versus Bisphosphonates (Alendronate) in GIOP